Alzheimer's drugs have been a monumental failure, and it looks as if bapineuzumab might get added to the list after failing its first phase 3 trial. With a number of new treatments in development for the disease and the patent cliff taking its toll, several pharma stocks are counting on success. Watch and find out which companies those are, what investors should be looking for in regard to this recent clinical failure, and one unique way to invest in this situation.
Considering how differently the companies involved in bapineuzumab's failure reacted to the disappointment, it's important to have large dividend-paying companies in your portfolio. Fortunately, the Dow is loaded with companies with solid dividend payouts and highly sustainable business models built for the long haul. The Motley Fool's new special free report, "The 3 Dow Stocks Dividend Investors Need," all have an X factor that makes them stand out from their illustrious peers. Download the report free for a limited time.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.